July 28, 2011

Sales growth of 6.9% thanks to Genzyme acquisition and performance of growth platforms. Positive impact from Genzyme on business EPS

 

Sales growth of 6.9% thanks to Genzyme acquisition and performance of growth platforms. Positive impact from Genzyme on business EPS

Commenting on the Group’s performance in Q2 2011, Sanofi Chief Executive Officer, Christopher A. Viehbacher said, “As expected, the second quarter is the most challenging this year, given the level of generic competition. Against this, growth platforms2 continue to perform well and strong progress has been achieved in the integration of Genzyme and Merial.”